RecruitingNot applicableNCT07371182
Luvometinib in Pediatric SS-LCH With Special-site Single/Multifocal Bone Lesions
Studying Langerhans cell histiocytosis
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- West China Second University Hospital
- Intervention
- Luvometinib(drug)
- Enrollment
- 62 enrolled
- Eligibility
- 0-18 years · All sexes
- Timeline
- 2026 – 2030
Study locations (11)
- The Second Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China
- The Second Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, China
- Affiliated Hospital of Guizhou Medical University, Guiyang, Guizhou, China
- Zunyi Medical University Affiliated Hospital, Guizhou Provincial Children's Hospital, Zunyi, Guizhou, China
- Jiangxi Provincial Children's Hospital, Nanchang, Jiangxi, China
- Xi'an Children's Hospital, Xi'an, Shaanxi, China
- Xi'an Northwest Women's and Children's Hospital, Xi'an, Shaanxi, China
- West China Second Hospital, Sichuan University, Chengdu, Sichuan, China
- The First Affiliated Hospital of Xinjiang Medical University, Ürümqi, Xinjiang, China
- Kunming Children's Hospital, Kunming, Yunan, China
- Anhui Provincial Children's Hospital, Hefei, China
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT07371182 on ClinicalTrials.govOther trials for Langerhans cell histiocytosis
Additional recruiting or active studies for the same condition.
- RECRUITINGNANCT07431060Modified LCH-III Regimen With or Without Luvometinib for Multisystem Pediatric Langerhans Cell HistiocytosisWest China Second University Hospital
- ACTIVE NOT RECRUITINGPHASE2NCT07204041Efficacy and Safety of XTD Regimen (Selinexor, Thalidomide and Dexamethasone) in Adult Patients With Relapsed/Refractory LCHCancer Institute and Hospital, Chinese Academy of Medical Sciences
- RECRUITINGPHASE2NCT07022834Real-world Study of Darafenib or Trametinib and Clofarabine for High-risk/Recurrent/Refractory Langerhans Cell Histiocytosis in ChildrenWest China Second University Hospital
- RECRUITINGPHASE2NCT07187193Efficacy and Safety of Low-Dose Cytarabine Combined With Thalidomide in Adult Patients With Untreated LCHCancer Institute and Hospital, Chinese Academy of Medical Sciences
- ENROLLING BY INVITATIONPHASE1NCT06902792Adebrelimab Combined With Trametinib in the Treatment of Refractory Recurrent Langerhans Cell Histiocytosis in Children and AdolescentsSecond Affiliated Hospital of Wenzhou Medical University
- RECRUITINGPHASE2NCT06582745Targeted Approach to Langerhans Cell Histiocytosis (LCH) Using MEK Inhibitor, TrametinibCook Children's Health Care System
- RECRUITINGPHASE2NCT05828069A Study With Tovorafenib (DAY101) as a Treatment Option for Progressive, Relapsed, or Refractory Langerhans Cell HistiocytosisNational Cancer Institute (NCI)
- RECRUITINGNCT06197204Biomarkers for Diagnostic, Prognostic and of Response to Treatment in Adult Langerhans Cell HistiocytosisAssistance Publique - Hôpitaux de Paris